Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)

Inclusion Criteria:

- Patients diagnosed with mature LLA-B cell (LLA-L3)

- Patients diagnosed with Burkitt´s and Burkitt´s Like Lymphoma

- Patients 15 years old or up

- Written Informed Consent signed

Exclusion Criteria:

- Serious complications related with LAL3/LB or Secondary illness:

Serious complications, uncontrollable, for example, sepsis, pneumonia with hypoxia,
shock, haemorrhage at diagnosis.

- Renal failure unconditional for the Lymphoma/Leukemia

- Heart failure or serious liver.

- Pulmonary obstructive disease or serious restrictive that not allow to treat the
patient with intensive chemotherapy.

- Secondary Lymphoma after chemotherapy or previous radiotherapy or second malignant
tumour.

- Known hypersensitivity to any foreign protein.

- Previous treatment with cytostatics of the LLA-B or Burkitt´s Lymphoma (exception:
administration on short time of glucocorticoids ≤ 7 days, one administration of
vincristine or cyclophosphamide, one cycle of CHOP, urgent administration of the
another cytostatics).

- With another malignant tumour in the last 5 year.

- Women in fertile age must give positive in the pregnancy test or nursing mother.

- Mental disability or emotional or psychiatric significant disorder were the patient
can't understand nor cooperate with treatment.

- Patients is enrolled in another clinical research study.